Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Advertisement